Category: 40644-16-4

Izevbekhai, Oisaemi Uduagele; Gitari, Wilson Mugera; Tavengwa, Nikita Tawanda; Ayinde, Wasiu Babatunde; Mudzielwana, Rabelani published an article in 2021, the title of the article was Synthesis and evaluation of the oil removal potential of 3-bromo-benzimidazolone polymer grafted silica gel.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one And the article contains the following content:

This work reports the synthesis of 3-bromo-benzimidazolone using melt condensation, its polymerization and functionalization on silica which was extracted from diatomaceous earth in our previous work. The synthesized compounds were characterized using FTIR, NMR, SEM-EDS and TEM. The FTIR and NMR spectra of the synthesized benzimidazolones showed the compounds to have several functional groups: A band due to Si-O-C at 1085.41 cm-1, a broad band at 3380 cm-1 and chem. shifts: pos. distortionless enhancement by polarization transfer (DEPT) 13C peaks (indicating lack of CH2 and CH3 groups), 1H NMR – 11.053 ppm (N-H), 7.086 ppm (Ar-H); 13C NMR – 155.34 ppm (CO), 101.04 ppm (C-Br) characteristic of benzimidazolones. SEM-EDS of the functionalized silica showed a rough irregular morphol. with Si and O as the major elements. Carbon was also present indicating that silica was successfully functionalized with 3-bromo-benzimidazolone and TEM showed interconnected smear-like particles arranged irregularly. The functionalized silica was then applied in the treatment of oily wastewater and factors like initial oil concentration, adsorption dosage and time were optimized using the central composite design of response surface methodol. in the design expert software. The amount of oil adsorbed was obtained by quantifying the total organic carbon using TOC test kits. Results showed that the optimum conditions for oil removal were 6650 mg L-1 oil concentration, with adsorbent dosage of 0.004 g and a contact time of 16 h. Under these conditions, the percentage adsorption was 97.9% with a desirability of 0.99. The materials were therefore seen to be applicable to field wastewaters. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to oil removal 3 bromo benzimidazolone polymer silica gel adsorption, Placeholder for records without volume info and other aspects.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On February 11, 2021, Pennington, Lewis D.; Woods, James R.; Huynh, Hoan; Aquila, Brian M.; Mugge, Ingo Andreas; Hu, Yuan; Choi, Younggi; Wynn, Thomas Andrew; Gerard, Baudouin; Bosanac, Todd; Vantangoli, Nicholas J. published a patent.Application of 40644-16-4 The title of the patent was Lactam-containing compounds for the treatment of pain. And the patent contained the following:

Provided herein are compounds I (R1= (halogen-substituted) C1-6 alkyl, C1-4 alkoxy; R2, R3, R4= H, (halogen-substituted) C1-4 alkyl, C1-4 alkoxy, OH, halogen; R5= H, C1-4 alkyl; X and R6 as defined in text) that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier and methods of treating pain in a subject in need thereof. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Application of 40644-16-4

The Article related to pharmaceutical composition pain, Pharmaceuticals: Pharmaceutics and other aspects.Application of 40644-16-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On October 14, 2021, Liu, Tao; Zhou, Shubao; Wang, Shaomeng; Zhang, Meng; Xu, Fuming; Zhou, Haibin; Aguilar, Angelo; Huang, Liyue published a patent.Safety of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one The title of the patent was Preparation of piperidine derivatives as menin inhibitors and methods of use for treating cancer. And the patent contained the following:

The present disclosure provides compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, L1, R2 B, Q and E are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin. :. The disclosure provides compounds represented by formula I, or a pharmaceutically acceptable salt thereof. The disclosure also provides compounds of formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin. Compounds of formula I wherein n is 0, 1 and 2; each Ra and each Rb are independently H and C1-4 alkyl; Rc is H and halo; each R4 is independently halo; Q is NHCO2R; R is C1-4 alkyl, C1-4 haloalkyl and CD3; B is imidazolylmethyl, pyrazolylmethyl, CH2OH, etc.; E is (un)substituted sulfonylphenyl, (un)substituted Ph, (un)substituted pyrimidinyl, etc.; L1 is CH2; and pharmaceutically acceptable salt thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their menin inhibitory activity. From the assay, it was determined that compound II exhibited IC50 values of less than 50 nM. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Safety of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to piperidine preparation menin inhibitor treatment cancer, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Safety of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bollenbach, Maud; Nemska, Simona; Wagner, Patrick; Camelin, Guillaume; Daubeuf, Francois; Obrecht, Adeline; Villa, Pascal; Rognan, Didier; Bihel, Frederic; Bourguignon, Jean-Jacques; Schmitt, Martine; Frossard, Nelly published an article in 2021, the title of the article was Design, synthesis and biological evaluation of arylpyridin-2-yl guanidine derivatives and cyclic mimetics as novel MSK1 inhibitors. An application in an asthma model.Category: imidazoles-derivatives And the article contains the following content:

In order to identify new MSK1 inhibitors, a screening of a library of low mol. weight compounds was performed, and the results highlighted the I [R = phenyl] ( IC50~18μM) as a starting hit for structure-activity relationship study. Derivatives, homologues and rigid mimetics of I [R = Ph, 2-furanyl, 3-pyridine, etc.] were designed, and all synthesized compounds were evaluated for their inhibitory activity towards MSK1. Among them, the non-cytotoxic 2-aminobenzimidazole was the most potent at inhibiting significantly: (i) MSK1 activity, (ii) the release of IL-6 in inflammatory conditions in vitro (IC50~2μM) and (iii) the inflammatory cell recruitment to the airways in a mouse model of asthma. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Category: imidazoles-derivatives

The Article related to arylpyridinyl guanidine preparation msk1 inhibitor antiasthmatic cytotoxicity sar, msk1, pyridine-2-yl guanidine, asthma, inflammation, kinase inhibitors, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 12, 2016, Cook, James H., II; Zusi, F. Christopher; Hill, Matthew D. published a patent.Application In Synthesis of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one The title of the patent was Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands. And the patent contained the following:

The invention relates to preparation of spiro quinuclidine oxazoloazole derivatives of formula I wherein X and R are as defined in the disclosure, which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Application In Synthesis of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to spiro quinuclidine oxazoloazole preparation alpha7 nicotinic acetylcholine receptor ligand, Heterocyclic Compounds (More Than One Hetero Atom): General and other aspects.Application In Synthesis of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On November 15, 2018, Kettle, Jason Grant; Bagal, Sharanjeet Kaur; Boyd, Scott; Eatherton, Andrew John; Fillery, Shaun Michael; Robb, Graeme Richard; Raubo, Piotr Antoni published a patent.Category: imidazoles-derivatives The title of the patent was Preparation of heteroaryl compounds as inhibitors as G12C mutant RAS proteins. And the patent contained the following:

The invention relates to compounds of formula I and pharmaceutically acceptable salts thereof; their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders. Compounds of formula I wherein ring A is aryl, monocyclic heteroaryl and bicyclic heteroaryl; R1 is C1-4 alkyl, halo, OH, etc.; n is 0 – 3; W is N and CR13; X is O and NR14; Y is CR15R16, CO, COCR21R22; R2 is H, CN, halo, etc.; R3 is H, C1-3 fluoroalkyl, OH and derivatives, etc.; R4 is H and Me, R5 is H and Me; R6 is H and CH2NMe2; R13 is H, C1-4 alkyl, halo, etc.; R15, R16 are independently H and C1-3 alkyl; R21 and R22 are independently H, C1-3 alkyl, and F; and pharmaceutically acceptable salt thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their KRas protein inhibitory activity (some data given). The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Category: imidazoles-derivatives

The Article related to pyrazinooxazepinoquinazoline preparation g12c mutant ras protein inhibitor anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Other 7-Membered Rings and other aspects.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 11, 2009, Berger, Dan Maarten; Levin, Jeremy Ian; Dutia, Minu Dhanjisha; Norton, Emily Boucher; Diamantidis, George published a patent.Application of 40644-16-4 The title of the patent was Preparation of aminosulfonylphenyl pyrazolo[1,5-a]pyrimidines as Raf kinase inhibitors.. And the patent contained the following:

Title compounds [I; R = H, halo, NO2, N3, cyano, CHO, CF3, OCF3, R5, OR5, N(R5)2, etc.; R1 = (substituted) heteroaryl, heterocyclyl; R2 = (substituted) aryl, heteroaryl, heterocyclyl; R3, R4 = H, (substituted) alkyl, cycloalkyl, heteroaryl; R5 = H, alkyl, alkenyl, alkynyl, cycloalkyl; N(R5)2 = atoms to form a substituted ring containing 2-7 C atoms], were prepared Thus, N-[2-(diethylamino)ethyl]-N-ethyl-3-[3-(3-hydroxyphenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]benzenesulfonamide (multistep preparation given) inhibited B-Raf kinase with IC50 <0.0003 μM. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Application of 40644-16-4

The Article related to phenylsulfonamide pyrazolopyrimidine preparation raf kinase inhibitor, cancer inflammation treatment aminosulfonylphenylpyrazolopyrimidine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Application of 40644-16-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 3, 2009, Levin, Jeremy Ian; Hopper, Darrin William; Torres, Nancy; Dutia, Minu Dhanjish; Berger, Dan Maarten; Wang, Xiaolun; Di Grandi, Martin Joseph; Zhang, Chunchun; Dunnick, Alejandro Lee published a patent.Synthetic Route of 40644-16-4 The title of the patent was Preparation of bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines as Raf kinase inhibitors.. And the patent contained the following:

Title compounds [I; R1 = (substituted) 5-7 membered heterocyclyl, heteroaryl; R2 = (substituted) (bicyclic) aryl, heteroaryl; R3-R5 = H, cyano, (substituted) alkyl, cycloalkyl aryl, heterocyclyl, heteroaryl, etc.], were prepared Thus, title compound 3-[7-[6-[(1-azabicyclo[2.2.2]oct-4-ylmethyl)amino]pyridin-3-yl]-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl]phenol [multistep preparation from 5-acetyl-2-bromopyridine, DMF di-Me acetal, 3-methoxyphenylacetonitrile, Me isonicotinate, and 1-(1-azabicyclo[2.2.2]oct-4-yl)methylamine given] inhibited B-Raf kinase with IC50 = 0.002 μM. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Synthetic Route of 40644-16-4

The Article related to pyrazolopyrimidine preparation raf kinase inhibitor, cancer inflammation treatment azabicyclooctylmethylaminopyridinylpyridin4ylpyrazolopyrimidinylphenol preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Synthetic Route of 40644-16-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On June 25, 2015, Cuevas Cordobes, Felix; Almansa-Rosales, Carmen; Garcia Lopez, Monica published a patent.Application of 40644-16-4 The title of the patent was Preparation of piperidine compounds as dual 蟽1 and 渭 opioid receptor modulators for treatment of pain. And the patent contained the following:

The invention relates to compounds of formula I having dual pharmacol. activity towards both the sigma (蟽1) and the 渭-opioid receptor and more particularly to piperidine compounds having this pharmacol. activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain. I [wherein m is 1 or 2; V1, V2, or V3 is selected from N or C while the others are C; R1 is hydroxy, (un)substituted -C(O)NH2, (un)substituted aryl, etc.; R2 is H, halo, (un)substituted (cyclo)alkyl, etc.; R5 is H, halo, hydroxy, (un)substituted alkyl, etc.; W, X, Y, and Z are selected from C, N, or O and together with C-atom form a 5-membered heterocyclic ring which may be substituted at W, X, Y, or Z or is fused at W and X to a further ring system] or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof are claimed and exemplified. II was prepared via reductive amination of 1-phenyl-1H-1,2,3-triazole-4-carbaldehyde with N-(3-(piperidin-4-yl)phenyl)propane-2-sulfonamide hydrochloride carried out using the reductive agent, sodium triacetoxyborohydride. I were evaluated for dual 蟽1- and 渭-opioid binding activity using radioligand assays (data given). The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Application of 40644-16-4

The Article related to piperidine compound preparation sigma mu opioid receptor modulator pain, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Application of 40644-16-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On March 26, 2015, Duggan, Karen Annette published a patent.Electric Literature of 40644-16-4 The title of the patent was Preparation of biphenyl propanamide compounds for the treatment of hypertension and/or fibrosis. And the patent contained the following:

The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis. The invention relates to novel terphenyl compounds of formula I [wherein A is selected from (un)substituted Ph, pyridinyl, indazolyl, etc.] or stereoisomers or pharmaceutically acceptable salts thereof, which are claimed and exemplified. II was prepared via a multistep procedure (preparation given). Antihypertensive activity of compounds of formula I was evaluated in spontaneously hypertensive rats on a high salt diet following 4 wks of therapy (data given). The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Electric Literature of 40644-16-4

The Article related to biphenyl propanamide compound preparation hypertension fibrosis, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Phenols, Thiophenols, and Derivatives Including Phenol and Thiophenol Ethers and Esters and other aspects.Electric Literature of 40644-16-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem